\contentsline {chapter}{\numberline {1}Introduction}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}Genetics and Molecular Biology in Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{5}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{5}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{6}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{7}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{7}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{8}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{9}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{10}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Established Sequencing Technologies}{11}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.3}Emerging Sequencing Technologies}{12}{subsubsubsection.1.1.3.3.3}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{14}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{14}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{15}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{16}{subsubsection.1.1.5.1}
\contentsline {subsubsection}{\numberline {1.1.5.2}The International Cancer Genome Consortium}{17}{subsubsection.1.1.5.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.1}Findings from Cancer Genomes}{17}{subsubsubsection.1.1.5.2.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.2}Genomic Comparisons Across Cancer Tissues}{19}{subsubsubsection.1.1.5.2.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.3}Cancer Genomic Data Resouces}{20}{subsubsubsection.1.1.5.2.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{20}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{21}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{22}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{22}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{23}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{23}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{24}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{27}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{28}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{28}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{29}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{30}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{30}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Evolution of Synthetic Lethality}{31}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{32}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{33}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{35}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{37}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{40}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{40}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{41}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{44}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{46}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{47}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{50}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{50}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{51}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{51}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{51}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{52}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{52}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{52}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{53}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{53}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{54}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{54}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occuring Mutations}{55}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{56}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{56}{section.1.4}
\contentsline {chapter}{\numberline {2}Methods and Resources}{61}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{61}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{61}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{62}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{63}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{63}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{63}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{65}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{65}{subsection.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.3.1}Candidate Triage and Integration with Screen Data}{66}{subsubsection.2.2.3.1}
\contentsline {section}{\numberline {2.3}Techniques}{67}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{67}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{68}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{68}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{68}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modeling and Simulations}{69}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic (Performance)}{70}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{70}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{71}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{71}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{72}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{72}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{72}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{74}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{74}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{74}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{77}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{79}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{79}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{81}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{82}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{86}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{87}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic lethality}{89}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic lethality}{91}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{93}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{99}{subsubsection.3.3.2.2}
\contentsline {subsubsubsection}{\numberline {3.3.2.2.1}Importance of Directional Testing}{101}{subsubsubsection.3.3.2.2.1}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{103}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{103}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{104}{subsubsection.3.4.1.1}
\contentsline {subsubsection}{\numberline {3.4.1.2}Ranking Based on Biological Context}{104}{subsubsection.3.4.1.2}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{105}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{110}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{110}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{111}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{111}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{113}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{113}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{113}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{114}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{114}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{115}{chapter.4}
\contentsline {paragraph}{Aims}{115}{section*.4}
\contentsline {paragraph}{Summary}{115}{section*.5}
\contentsline {section}{\numberline {4.1}Synthetic lethal genes in breast cancer}{117}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic lethal pathways in breast cancer}{119}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression profiles of synthetic lethal partners}{119}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup pathway analysis}{120}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparison of synthetic lethal gene candidates}{122}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Comparison with differential expression}{122}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Comparison with primary siRNA screen candidates}{122}{subsection.4.2.2}
\contentsline {subsubsection}{\numberline {4.2.2.1}Comparison with correlation}{125}{subsubsection.4.2.2.1}
\contentsline {subsubsection}{\numberline {4.2.2.2}Comparison with viability}{126}{subsubsection.4.2.2.2}
\contentsline {subsubsection}{\numberline {4.2.2.3}Comparison of screen at pathway level}{126}{subsubsection.4.2.2.3}
\contentsline {subsubsubsection}{\numberline {4.2.2.3.1}Resampling of genes for pathway enrichment}{127}{subsubsubsection.4.2.2.3.1}
\contentsline {subsection}{\numberline {4.2.3}Comparison with secondary screen siRNA screen candidates}{131}{subsection.4.2.3}
\contentsline {subsubsection}{\numberline {4.2.3.1}Comparison of candidate SL Pathways}{131}{subsubsection.4.2.3.1}
\contentsline {section}{\numberline {4.3}Mutation, Copy Number, and Methylation}{131}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Synthetic lethality by DNA copy number}{133}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Synthetic lethality by somatic mutation}{133}{subsection.4.3.2}
\contentsline {subsubsection}{\numberline {4.3.2.1}Mutation analysis}{133}{subsubsection.4.3.2.1}
\contentsline {subsection}{\numberline {4.3.3}ANOVA of Expression Predictors}{133}{subsection.4.3.3}
\contentsline {section}{\numberline {4.4}Global Synthetic Lethality}{134}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Hub Genes}{134}{subsection.4.4.1}
\contentsline {section}{\numberline {4.5}Metagene Analysis}{134}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Pathway expression}{134}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Somatic mutation}{134}{subsection.4.5.2}
\contentsline {subsection}{\numberline {4.5.3}Synthetic lethal metagenes}{134}{subsection.4.5.3}
\contentsline {section}{\numberline {4.6}Replication in stomach cancer}{134}{section.4.6}
\contentsline {section}{\numberline {4.7}Replication in cell line encyclopaedia}{135}{section.4.7}
\contentsline {section}{\numberline {4.8}Summary}{135}{section.4.8}
\contentsline {chapter}{\numberline {5}Synthetic Lethal Pathway Structure}{142}{chapter.5}
\contentsline {paragraph}{Aims}{142}{section*.60}
\contentsline {paragraph}{Summary}{142}{section*.61}
\contentsline {section}{\numberline {5.1}Reactome Network structure and Information Centrality as a measure of gene essentiality}{143}{section.5.1}
\contentsline {section}{\numberline {5.2}Synthetic lethal genes in synthetic lethal pathways}{143}{section.5.2}
\contentsline {section}{\numberline {5.3}Centrality and connectivity of synthetic lethal genes}{143}{section.5.3}
\contentsline {section}{\numberline {5.4}Upstream or downstream synthetic lethal candidates}{143}{section.5.4}
\contentsline {section}{\numberline {5.5}Hierachical approach}{143}{section.5.5}
\contentsline {section}{\numberline {5.6}Discussion}{143}{section.5.6}
\contentsline {section}{\numberline {5.7}Conclusion}{143}{section.5.7}
\contentsline {chapter}{\numberline {6}Simulation and Modeling of Synthetic Lethal Pathways}{144}{chapter.6}
\contentsline {paragraph}{Aims}{144}{section*.62}
\contentsline {paragraph}{Summary}{144}{section*.63}
\contentsline {section}{\numberline {6.1}Simulations and Modelling Synthetic Lethality in Expression Data}{146}{section.6.1}
\contentsline {section}{\numberline {6.2}Simulations over simple graph structures}{147}{section.6.2}
\contentsline {subsection}{\numberline {6.2.1}Performance}{147}{subsection.6.2.1}
\contentsline {subsection}{\numberline {6.2.2}Synthetic lethality across graph stuctures}{147}{subsection.6.2.2}
\contentsline {subsection}{\numberline {6.2.3}Performance with inhibition links}{147}{subsection.6.2.3}
\contentsline {subsection}{\numberline {6.2.4}Performance with 20,000 genes}{147}{subsection.6.2.4}
\contentsline {section}{\numberline {6.3}Simulations over pathway-based graphs}{147}{section.6.3}
\contentsline {section}{\numberline {6.4}Comparing methods}{147}{section.6.4}
\contentsline {subsection}{\numberline {6.4.1}SLIPT and Chi-Squared}{147}{subsection.6.4.1}
\contentsline {subsubsection}{\numberline {6.4.1.1}Correlated query genes}{147}{subsubsection.6.4.1.1}
\contentsline {subsection}{\numberline {6.4.2}Correlation}{147}{subsection.6.4.2}
\contentsline {subsection}{\numberline {6.4.3}Bimodality with BiSEp}{147}{subsection.6.4.3}
\contentsline {chapter}{\numberline {7}Discussion}{148}{chapter.7}
\contentsline {paragraph}{Aims}{148}{section*.64}
\contentsline {paragraph}{Summary}{148}{section*.65}
\contentsline {section}{\numberline {7.1}Significance}{150}{section.7.1}
\contentsline {section}{\numberline {7.2}Future Directions}{151}{section.7.2}
\contentsline {section}{\numberline {7.3}Conclusion}{152}{section.7.3}
\contentsline {chapter}{\numberline {8}Conclusion}{153}{chapter.8}
\contentsline {chapter}{\numberline {A}Sample Quality}{154}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{154}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast}{156}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{160}{appendix.B}
\contentsline {chapter}{\numberline {C}Secondary Screen Data}{169}{appendix.C}
\contentsline {chapter}{\numberline {D}Mutation Analysis in Breast Cancer}{171}{appendix.D}
\contentsline {section}{\numberline {D.1}Synthetic Lethal Genes and Pathways}{171}{section.D.1}
\contentsline {section}{\numberline {D.2}Comparison to Primary Screen}{175}{section.D.2}
\contentsline {section}{\numberline {D.3}Resampling Analysis}{177}{section.D.3}
\contentsline {section}{\numberline {D.4}Metagene Analysis}{179}{section.D.4}
\contentsline {section}{\numberline {D.5}Mutation Variation}{180}{section.D.5}
\contentsline {subsection}{\numberline {D.5.1}Mutation Frequency}{180}{subsection.D.5.1}
\contentsline {subsection}{\numberline {D.5.2}PI3K Mutation Expression}{181}{subsection.D.5.2}
\contentsline {section}{\numberline {D.6}Compare SLIPT genes}{186}{section.D.6}
\contentsline {chapter}{\numberline {E}Expression Analysis in Stomach Cancer}{187}{appendix.E}
\contentsline {chapter}{\numberline {F}Mutation Analysis in Stomach Cancer}{188}{appendix.F}
